Lung cancer
EA5181
Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable
Trial overview
Topic
EA5181
Disease
Lung cancer treatment and diagnosis
Description
Primary Objective:The primary objective of the trial is to determine whether concurrent MEDI4736 (durvalumab) with cytoxic chemo/radiation improves overall survival (OS) in addition to a standard therapy (chemotherapy and radiation followed by consolidative MEDI4736 (durvalumab)). Secondary objectives include estimation of progression-free survival, best objective response, incidence of local/distant progression, and toxicity.Patient Population:Patients with unresectable Stage 3 Non-small cell lung cancer.
Physicians
Frank A. Vicini
MD, FACR, FASTRO, FABS
Radiation Oncologist
Farmington Hills (Radiation oncology) +3
Eduardo B. Fernandez
MD, PhD, DABR, FACRO, FASTRO
Radiation Oncologist
Aventura (Radiation oncology) +3
